Humacyte (NASDAQ:HUMA) Price Target Raised to $17.00 at Benchmark

Humacyte (NASDAQ:HUMA) had its target price raised by Benchmark from $15.00 to $17.00 in a report published on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other equities analysts have also commented on HUMA. D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of Humacyte in a research report on Friday. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target (up from $12.00) on shares of Humacyte in a report on Friday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a report on Friday, September 20th. Finally, TD Cowen restated a “buy” rating and set a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Humacyte currently has an average rating of “Buy” and a consensus price target of $13.71.

Humacyte Trading Up 0.2 %

Shares of HUMA opened at $4.65 on Monday. Humacyte has a 12 month low of $2.48 and a 12 month high of $9.97. The stock’s 50-day moving average is $4.81 and its two-hundred day moving average is $5.81. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. The stock has a market cap of $585.24 million, a PE ratio of -3.47 and a beta of 1.38.

Insiders Place Their Bets

In related news, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the sale, the director now directly owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Laura E. Niklason sold 261,369 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total value of $1,150,023.60. Following the transaction, the chief executive officer now owns 1,730,884 shares in the company, valued at $7,615,889.60. This trade represents a 13.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,500,000 shares of company stock valued at $6,606,799 in the last ninety days. Corporate insiders own 11.20% of the company’s stock.

Institutional Trading of Humacyte

Several institutional investors have recently added to or reduced their stakes in the business. nVerses Capital LLC acquired a new position in shares of Humacyte in the 2nd quarter valued at about $28,000. Concurrent Investment Advisors LLC bought a new position in Humacyte in the third quarter worth about $75,000. Principal Financial Group Inc. acquired a new position in Humacyte in the second quarter valued at approximately $83,000. FORA Capital LLC bought a new position in shares of Humacyte during the third quarter valued at approximately $96,000. Finally, Profund Advisors LLC acquired a new stake in shares of Humacyte during the 2nd quarter worth approximately $97,000. Institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.